Glaukos (NYSE:GKOS) Receives Buy Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Glaukos (NYSE:GKOS) in a research note released on Monday,Benzinga reports. BTIG Research currently has a $104.00 price target on the medical instruments supplier’s stock.

A number of other research firms also recently weighed in on GKOS. Truist Financial reduced their target price on shares of Glaukos from $126.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Citigroup reduced their target price on shares of Glaukos from $140.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th. William Blair raised shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $116.92.

Glaukos Stock Down 8.8%

GKOS opened at $79.48 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company’s 50-day moving average is $87.60 and its 200 day moving average is $92.18. Glaukos has a fifty-two week low of $75.36 and a fifty-two week high of $163.71. The firm has a market capitalization of $4.56 billion, a P/E ratio of -48.17 and a beta of 0.76.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period last year, the firm earned ($0.52) earnings per share. The firm’s revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Research analysts expect that Glaukos will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Glaukos

Hedge funds and other institutional investors have recently modified their holdings of the business. Bessemer Group Inc. grew its stake in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 158 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 159 shares in the last quarter. Park Place Capital Corp grew its stake in Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 162 shares in the last quarter. AlphaQuest LLC grew its stake in Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 633 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 136 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.